Hong Kong to Host Asia’s First Commercial Plant for Key Cancer-Fighting Isotope
Listen to the full version
A new company is setting up a facility in Hong Kong to produce a rare radioisotope used in advanced cancer treatments, a move that would mark Asia’s first commercial production of the in-demand material amid a global supply crunch.
Asia Advanced Isotope Technology Ltd. announced Monday that it will establish a production line for the radioisotope Actinium-225 (Ac-225) in Hong Kong’s Tai Po InnoPark, with production expected to begin in 2027. The company plans to invest about HK$600 million ($76.8 million) in the project, which has also received support from a government program that is expected to provide HK$140 million in subsidies.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- DIGEST HUB
Digest Hub
Back
- Asia Advanced Isotope Technology Ltd. will invest HK$600 million to produce Actinium-225 in Hong Kong, starting in 2027, with HK$140 million in government subsidies.
- The facility will be Asia’s first commercial production of this rare cancer-treatment isotope, addressing a regional supply gap amid rising global demand.
- The project will also develop other isotopes and collaborate with local universities, positioning Hong Kong as a regional hub for radiopharmaceuticals.
- Asia Advanced Isotope Technology Ltd.
- Asia Advanced Isotope Technology Ltd. is a company established in 2024 that will set up a facility in Hong Kong to produce Actinium-225 (Ac-225), a rare radioisotope used in advanced cancer treatments. This facility will be Asia's first commercial production of Ac-225, intending to address a global supply crunch. The company plans to invest approximately HK$600 million in the project.
- Novartis AG
- Novartis AG is a pharmaceutical company that produces Pluvicto, a targeted radiopharmaceutical for treating prostate cancer. This drug saw a significant sales increase of 42% year-on-year, reaching $1.39 billion in 2024, demonstrating the substantial commercial potential of radiopharmaceuticals.
- 2024：
- Asia Advanced Isotope Technology Ltd. was established.
- 2024：
- Novartis AG’s Pluvicto posted a 42% year-on-year sales increase to $1.39 billion.
- 2025：
- The company aims to position Hong Kong as its Asian hub.
- 2025：
- Asia Advanced Isotope Technology Ltd. plans to collaborate with local universities to develop new superconducting cyclotrons and cultivate local talent.
- 2025：
- The project receives support from the Hong Kong government’s New Industrialisation Acceleration Scheme.
- 2025：
- Sun Dong states government commitment to using innovation for industrial upgrades and promoting economic development.
- 2025-10-13：
- Asia Advanced Isotope Technology Ltd. announced it will establish a facility for Ac-225 production in Hong Kong’s Tai Po InnoPark.
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新